DXCM Stock Overview A medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More details
Rewards Risk Analysis DXCM passed our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for DexCom Historical stock prices Current Share Price US$78.15 52 Week High US$130.70 52 Week Low US$58.07 Beta 1.13 1 Month Change 11.29% 3 Month Change 23.07% 1 Year Change -28.88% 3 Year Change -38.56% 5 Year Change n/a Change since IPO -15.88%
Recent News & Updates
Third quarter 2024 earnings released: EPS: US$0.34 (vs US$0.31 in 3Q 2023) Oct 25
DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024 Oct 25
Kessler Topaz Meltzer & Check, LLP Files Class Action Lawsuit Against Dexcom, Inc Oct 12
DexCom, Inc. to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium Sep 04
Stelo by Dexcom, the First Over-The-Counter Glucose Biosensor in the U.S., Is Now Available Aug 26 Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of DexCom, Inc Aug 22
See more updates
Third quarter 2024 earnings released: EPS: US$0.34 (vs US$0.31 in 3Q 2023) Oct 25
DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024 Oct 25
Kessler Topaz Meltzer & Check, LLP Files Class Action Lawsuit Against Dexcom, Inc Oct 12
DexCom, Inc. to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium Sep 04
Stelo by Dexcom, the First Over-The-Counter Glucose Biosensor in the U.S., Is Now Available Aug 26 Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of DexCom, Inc Aug 22
Investor sentiment deteriorates as stock falls 36% Aug 01
Now 7.0% undervalued after recent price drop Jul 26
Second quarter 2024 earnings released: EPS: US$0.36 (vs US$0.30 in 2Q 2023) Jul 26 DexCom, Inc. Updates Earnings Guidance for the Year 2024
DexCom, Inc. to Report Q2, 2024 Results on Jul 25, 2024 Jun 28
Dexcom Showcases Extensive Clinical Data At ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People with Type 2 Diabetes Jun 21
Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects Directly to Apple Watch in the United States Jun 06
Dexcom Wins Access to Dexcom One for 100,000 People Living with Type 2 Diabetes Jun 05
DexCom, Inc. Provides Earnings Guidance for the Year 2024 Apr 27
First quarter 2024 earnings released: EPS: US$0.38 (vs US$0.13 in 1Q 2023) Apr 26
DexCom, Inc., Annual General Meeting, May 22, 2024 Apr 24
New minor risk - Shareholder dilution Apr 24
DexCom, Inc., Annual General Meeting, May 22, 2024 Apr 23
DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024 Apr 03
Executive Chairman recently sold €3.7m worth of stock Mar 15 DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor
Now 21% undervalued Feb 12
Full year 2023 earnings released: EPS: US$1.40 (vs US$0.88 in FY 2022) Feb 09
DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024 Feb 09
DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People Feb 06
Executive Chairman recently sold €4.2m worth of stock Jan 19
Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa Jan 15
DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024 Jan 09
Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024 Jan 08
Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump Dec 06
Insufficient new directors Nov 01 DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.
Third quarter 2023 earnings released: EPS: US$0.31 (vs US$0.26 in 3Q 2022) Oct 27
Now 22% undervalued after recent price drop Oct 06
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD Oct 05
DexCom, Inc. to Report Q3, 2023 Results on Oct 26, 2023 Sep 30
DexCom, Inc Announces the Availability of Its Dexcom One Real-Time CGM Sensor Via Reimbursement, in France Sep 13
DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors Aug 29
DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023 Jul 28
Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.13 in 2Q 2022) Jul 28 DexCom, Inc. to Report Q2, 2023 Results on Jul 27, 2023 Jul 07
Dexcom, Inc. Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System with Unmatched Accuracy Coming to Canadians Jul 06
DexCom, Inc. Updates Earnings Guidance for the Year 2025 Jun 24
First quarter 2023 earnings released: EPS: US$0.13 (vs US$0.25 in 1Q 2022) Apr 29
DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023 Feb 11
Full year 2022 earnings released: EPS: US$0.88 (vs US$0.40 in FY 2021) Feb 10
Executive Chairman recently sold €4.5m worth of stock Jan 25
Dexcom, Inc.'s G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program Jan 18 DexCom, Inc. to Report Q4, 2022 Results on Feb 09, 2023
Dexcom, Inc. Receives FDA Clearance of Next-Generation Dexcom G7 Continuous Glucose Monitoring System Dec 10
Third quarter 2022 earnings released: EPS: US$0.26 (vs US$0.18 in 3Q 2021) Oct 28
DexCom, Inc. Provides Earnings Guidance for the Year 2022 Oct 28
DexCom, Inc. Announces the Launch of Dexcom U Oct 25
DexCom, Inc. Announces Launch of Dexcom G7 in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System Oct 06
DexCom, Inc. to Report Q3, 2022 Results on Oct 27, 2022 Sep 30
DexCom, Inc. Promotes Jacob S. Leach to Chief Operating Officer Sep 01
DexCom, Inc. Announces One Real-Time Continuous Glucose Monitoring (rt-CGM) System Available on Prescription in the UK Aug 02
Second quarter 2022 earnings released: EPS: US$0.13 (vs US$0.20 in 2Q 2021) Jul 30
DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $700 million worth of its shares. Jul 30
DexCom, Inc. Revises Earnings Guidance for the Full Year 2022 Jul 29
DexCom, Inc. Announces Resignation of Chad M. Patterson as Executive Vice President, Global Marketing, Effective July 15, 2022 Jul 09
DexCom, Inc. to Report Q2, 2022 Results on Jul 28, 2022 Jul 01
Dexcom Says Not in Active Merger Talks Jun 02
Dexcom Reportedly in Talks to Acquire Insulet May 24
First quarter 2022 earnings released: EPS: US$1.00 (vs US$0.42 in 1Q 2021) Apr 29
DexCom, Inc. Showcases Expanded CGM Portfolio at International ATTD Conference Apr 26
Now 23% undervalued Apr 11
Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices Apr 03
DexCom, Inc. to Report Q1, 2022 Results on Apr 28, 2022 Apr 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 11
DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022 Feb 11
Executive Chairman recently sold €7.6m worth of stock Jan 23
Dexcom, Inc. Reports Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2021; Revenue Guidance for the Fiscal Year 2022 Jan 12
Insider recently sold €485k worth of stock Nov 24
Third quarter 2021 earnings released: EPS US$0.73 (vs US$0.75 in 3Q 2020) Oct 29
Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People with Type 1 Diabetes Oct 02
Dexcom, Inc. Announces Non-insured Health Benefits Program Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy Sep 14
Chief Operating Officer recently sold €4.3m worth of stock Sep 12
Second quarter 2021 earnings released: EPS US$0.65 (vs US$0.49 in 2Q 2020) Jul 30
FDA Clears DexCom, Inc.'s Real-Time APIs for Third-Party Apps and Devices Jul 16 Shareholder Returns DXCM AT Medical Equipment AT Market 7D 5.4% -1.4% -1.4% 1Y -28.9% 5.4% -1.6%
See full shareholder returns
Return vs Market: DXCM underperformed the Austrian Market which returned -1.6% over the past year.
Price Volatility Is DXCM's price volatile compared to industry and market? DXCM volatility DXCM Average Weekly Movement 4.6% Medical Equipment Industry Average Movement 6.1% Market Average Movement 3.8% 10% most volatile stocks in AT Market 6.2% 10% least volatile stocks in AT Market 2.1%
Stable Share Price: DXCM has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: DXCM's weekly volatility (5%) has been stable over the past year.
About the Company DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Show more DexCom, Inc. Fundamentals Summary How do DexCom's earnings and revenue compare to its market cap? DXCM fundamental statistics Market cap €29.96b Earnings (TTM ) €652.48m Revenue (TTM ) €3.79b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DXCM income statement (TTM ) Revenue US$3.95b Cost of Revenue US$1.52b Gross Profit US$2.44b Other Expenses US$1.76b Earnings US$680.80m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 1.74 Gross Margin 61.68% Net Profit Margin 17.22% Debt/Equity Ratio 123.3%
How did DXCM perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 09:38 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources DexCom, Inc. is covered by 63 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Francis Mainwaring Atlantic Equities LLP Anand Vankawala Avondale Partners null null Baird
Show 60 more analysts 